While they also failed to indicate an association between serum IGF-1 levels and IGFBP-1, -2, and -3 levels between MS patients and the healthy controls, a significant increase in serum levels of IGF-1 (52%), IGFBP-2 (86%), and IGFBP-3 (18%) were yielded in Hosback et al. ‘s findings comparing MS patients to the control group [16]. This evidence concerns the gene IGFBP1 and myeloid sarcoma.